ARMP News & Events

Armata Pharmaceuticals has received an additional $2.5M of non-dilutive funding pursuant to a previously announced Department of Defense award, received through the Medical Technology Enterprise Consortium and managed by the Naval Medical Research Command - Naval Advanced Medical Development with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. The award, which now totals $28.7M, supports the development of Armata's lead clinical candidate AP-SA02, for adjunct treatment of complicated Staphylococcus aureus bacteremia caused by methicillin-sensitive S. aureus or methicillin resistant S. aureus. The additional $2.5M is intended to fund key activities to support Phase 3 readiness of AP-SA02.

Reports Q1 revenue $0.8M vs. $0.5M last year. "Our top priority in 2026 is advancing Armata's lead Staphylococcus aureus therapeutic phage candidate, AP-SA02, into a Phase 3 superiority study in complicated S. aureus bacteremia," said CEO Deborah Birx. "We are focused on initiating a rigorously designed and operationally efficient study designed to support a future Biologics License Application submission and potential registration. If successful, AP-SA02 has the potential to offer an important new treatment option for patients facing this serious and often life-threatening infection...I also want to highlight other important recent developments including the granting by the FDA of both Qualified Infectious Disease Product and Fast Track Designation for AP-SA02...We are pleased to have the ongoing backing of Innoviva, our largest shareholder who has supported us since 2020, in providing additional financing that will help us to advance AP-SA02, and we are continuing to pursue additional sources of funding, including non-dilutive sources".

Armata Pharmaceuticals announced that the U.S. FDA has granted Fast Track Designation to AP-SA02, the company's intravenously administered Staphylococcus aureus multi-phage product candidate, for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus or methicillin resistant S. aureus.